Gusacitinib Explained

Gusacitinib (ASN002) is an investigational drug which acts as a pan-Janus kinase inhibitor, binding with similar affinity at JAK1, JAK2, JAK3 and TYK2, and also inhibiting spleen tyrosine kinase (SYK).^[1] It is taken orally and was developed for the treatment of eczema and dermatitis.^{[2] [3] [4]}

See also

• Delgocitinib
• Izencitinib
• Tofacitinib

Notes and References

1. Raghuvanshi R, Bharate SB . Recent Developments in the Use of Kinase Inhibitors for Management of Viral Infections . Journal of Medicinal Chemistry . 65 . 2 . 893–921 . January 2022 . 33539089 . 10.1021/acs.jmedchem.0c01467 .
2. Bissonnette R, Maari C, Forman S, Bhatia N, Lee M, Fowler J, Tyring S, Pariser D, Sofen H, Dhawan S, Zook M, Zammit DJ, Usansky H, Denis L, Rao N, Song T, Pavel AB, Guttman-Yassky E . The oral Janus kinase/spleen tyrosine kinase inhibitor ASN002 demonstrates efficacy and improves associated systemic inflammation in patients with moderate-to-severe atopic dermatitis: results from a randomized double-blind placebo-controlled study . The British Journal of Dermatology . 181 . 4 . 733–742 . October 2019 . 30919407 . 10.1111/bjd.17932 . 6850605 .
3. Zalewski A, Szepietowski JC . Topical and systemic JAK inhibitors in hand eczema - a narrative review . Expert Review of Clinical Immunology . 19 . 4 . 365–373 . April 2023 . 36708316 . 10.1080/1744666X.2023.2174526 .
4. Jimenez PA, Sofen HL, Bissonnette R, Lee M, Fowler J, Zammit DJ, Chen Y, Rao N, Denis L, Gupta S . Oral spleen tyrosine kinase/Janus Kinase inhibitor gusacitinib for the treatment of chronic hand eczema: Results of a randomized phase 2 study . Journal of the American Academy of Dermatology . 89 . 2 . 235–242 . August 2023 . 37094653 . 10.1016/j.jaad.2023.04.027 . free .